ExploreWatchlistsPricing
  1. JP-listed companies
  2. K Pharma,Inc.
  3. Financials
  4. Total current liabilities

K Pharma,Inc. (4896)

Market cap
¥7.9B
P/E ratio
-4.9x
K Pharma develops treatments for neurological diseases like ALS and Alzheimer's using iPS cell technology and regenerative medicine based on Keio University research.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndTotal current liabilities (Million JPY)YoY (%)
Dec 31, 2025102+60.37%
Dec 31, 202463-64.44%
Dec 31, 2023178+429.88%
Dec 31, 202234+44.12%
Dec 31, 202123

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat